The potential mega-deal between big pharma giants Pfizer (NYSE: PFE) and AstraZeneca (NYSE: AZN) is officially off, but of the two companies, which is under the most pressure?
Pfizer is surrounded by questions after not being able to close its acquisition and AstraZeneca has to deliver on the claims Pfizer was undervaluing the company's drug pipeline.
In this video, Motley Fool healthcare analysts David Williamson and Michael Douglass discuss the post-mortem on the would be inversion deal along with the challenges both stocks face going forward. Which CEO is in the hot seat? Watch and find out.
Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
The article The Biggest Loser of 2014's Mega Merger Mess originally appeared on Fool.com.David Williamson owns shares of Pfizer. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.